Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.

Adeela Mushtaq,Ahmad Iftikhar,Hamza Hassan,Midhat Lakhani,Fnu Sagar,Ahmad Kamal,Umar Zahid,Zeeshan Ali,Faryal Razzaq,Muhammad Abu Zar,Syeda Fatima Hassan,Ahmad Safdar,Sreejata Raychaudhuri,Faiz Anwer

Clinical Lymphoma Myeloma and Leukemia（2019）

引用 11|浏览4

暂无评分

摘要

Three-drug Pom regimens yielded double the response rates compared to Pom + LoDex (pooled ORR, 61.9% vs. 35.7%), with bortezomib + Pom + LoDex and carfilzomib-Pom + LoDex demonstrating better outcomes than other regimens.

查看译文

关键词

Adverse event,Immunomodulator,Outcome,Overall response,Pom-dex

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要